id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0626-0032,FDA,FDA-2008-D-0626,See FDA-2008-D-0626-0034,Supporting & Related Material,C-Comment (Supporting and Related Material),2009-08-20T04:00:00Z,2009,8,,,2012-03-24T19:34:47Z,,0,0,0900006480a0debe
FDA-2008-D-0626-0033,FDA,FDA-2008-D-0626,See FDA-2009-D-0626-0034,Supporting & Related Material,,2009-08-20T00:00:00Z,2009,8,,,2012-03-24T19:36:37Z,,0,1,0900006480a04768
FDA-2008-D-0626-0012,FDA,FDA-2008-D-0626,Draft Guidance for Industry: Bioequivalence Recommendation for Vancomycin HCl; Extension of Comment Period,Notice,NEC-Notice of Extension,2009-02-10T05:00:00Z,2009,2,2009-02-10T05:00:00Z,2009-03-20T03:59:59Z,2009-02-10T21:34:33Z,E9-02800,0,0,090000648084faeb